Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV-Primed Children in the Philippines

J Infect Dis. 2018 Jan 30;217(4):567-571. doi: 10.1093/infdis/jix601.

Authors

Maria Rosario Capeding¹, Edison R Alberto¹, Alain Bouckenooghe², Thelma M Laot³, Danaya Chansinghakul⁴, Céline Monfredo⁵, Tifany Machabert⁶, Emmanuel Feroldi⁷

Affiliations

¹ Research Institute for Tropical Medicine, Muntinlupa City, Philippines.
² Clinical Sciences and Medical Affairs, Sanofi Pasteur, Singapore.
³ Clinical Sciences, Sanofi Pasteur, Taguig City, Philippines.
⁴ Clinical Sciences, Sanofi Pasteur, Bangkok, Thailand.
⁵ Clinical Programs, Sanofi Pasteur, Marcy l'Etoile.
⁶ Soladis, Lyon.
⁷ Global Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France.

Abstract

Keywords: IMOJEV; JE-CV; Japanese encephalitis; Philippines; live attenuated Japanese encephalitis vaccine.

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.

Publication types

Clinical Trial, Phase III
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Neutralizing / blood
Antibodies, Viral / blood*
Antibody Formation*
Child, Preschool
Encephalitis Virus, Japanese / immunology*
Encephalitis, Japanese / prevention & control*
Follow-Up Studies
Humans
Immunization, Secondary*
Japanese Encephalitis Vaccines / administration & dosage*
Japanese Encephalitis Vaccines / immunology*
Male
Philippines

Substances

Antibodies, Neutralizing
Antibodies, Viral
Japanese Encephalitis Vaccines

Associated data

ClinicalTrials.gov/NCT01190228